Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-50 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesia.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized by CYP3A4 to norfentanyl and other inactive metabolites. Minimal metabolism via CYP3A5. Less than 1% excreted unchanged in urine.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~80–85% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein (AAG).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
3–8 L/kg (mean ~4 L/kg). High Vd indicates extensive tissue distribution (e.g., muscle, fat). Clinical meaning: large reservoir; slow redistribution contributes to long half-life.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Transdermal: ~92% relative to IV fentanyl (due to first-pass metabolism avoidance; absolute bioavailability ~45% for gel reservoir, ~40% for matrix patch). Not used orally (poor bioavailability <30%).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-59 m L/min: reduce dose by 50% and monitor closely. GFR <30 m L/min: contraindicated due to accumulation of active metabolite.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% and monitor. Child-Pugh Class C: avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Approved for opioid-tolerant children ≥2 years; dose based on morphine equivalent daily dose (MEDD) conversion; apply system every 72 hours; initial dose not to exceed 25 mcg/h.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Start at lowest available dose (25 mcg/h) and titrate slowly; monitor for respiratory depression, sedation, and constipation; consider reduced clearance and increased sensitivity.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: RISK OF MEDICATION ERRORS, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION IN CHILDREN.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, especially in non-opioid-tolerant patients or with dose initiation/titration,Risk of hypotension, bradycardia, and QT prolongation,Risk of serotonin syndrome with serotonergic drugs,Risk of adrenal insufficiency with prolonged use,Risk of severe hypotension in patients with compromised ability to maintain blood pressure,Use caution in patients with head injury, increased intracranial pressure, or impaired consciousness,May obscure the course of acute abdominal conditions,Risk of withdrawal with abrupt discontinuation,Application site reactions,Fever may increase fentanyl absorption through the skin,Not indicated for acute or postoperative pain,Should be used only in opioid-tolerant patients for chronic pain
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to fentanyl or any component of the system,Opioid-non-tolerant patients (including patients with acute or postoperative pain),Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Suspected or known paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid grapefruit and grapefruit juice as they may increase fentanyl levels. No other significant food interactions.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression at birth. Avoid during labor due to risk of neonatal respiratory depression.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Fentanyl is excreted in breast milk. Milk-to-plasma ratio is approximately 0.87-1.0. Use caution; monitor infant for drowsiness, feeding difficulties, and respiratory depression. American Academy of Pediatrics recommends use only if benefit outweighs risk.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Pregnancy can increase fentanyl clearance due to increased plasma volume and hepatic metabolism. Gradual dose increments may be needed to maintain analgesia. However, avoid use during labor and delivery. If required, use lowest effective dose and have resuscitation equipment available.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Convert oral morphine to transdermal fentanyl using a 100:1 ratio (e.g., oral morphine 100 mg/day = fentanyl 100 mcg/hr patch). Rotate patch sites every 72 hours to avoid skin irritation; apply to non-irradiated, intact skin. Do not cut or damage the patch. Initiate only in opioid-tolerant patients. Titrate no more frequently than every 72 hours. Monitor for respiratory depression, especially in opioid-naive patients, COPD, or sleep apnea. Naloxone may be needed but duration of fentanyl action may exceed naloxone's effect. Heat exposure (e.g., fever, heating pads) increases absorption and risk of toxicity. Remove old patch before applying new one.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Apply patch to flat, non-hairy skin on chest, back, or upper arm; avoid irritated or scarred skin.,Wash hands after applying; do not touch the gel or cut the patch.,Dispose of used patches by folding adhesive sides together and flushing down toilet or placing in child-resistant container.,Avoid heating pads, hot tubs, electric blankets, or sunbathing while wearing patch.,Do not stop or change dose without talking to doctor; withdrawal may occur.,Keep patches out of reach of children and pets; accidental exposure can be fatal.,Common side effects include nausea, constipation, drowsiness, and dizziness.,Seek emergency care if you have trouble breathing, slow heartbeat, or severe drowsiness.,Do not drink alcohol or take other sedatives without doctor approval.,If patch falls off, apply a new one at a different site and note the time to track 72-hour schedule.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-50 vs ALFENTA, answered by our medical review team.
DURAGESIC-50 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-50 and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-50 is: Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-50 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-50 is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause n. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.